Detalhe da pesquisa
1.
A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.
Support Care Cancer
; 26(4): 1169-1179, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116406
2.
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer.
Front Oncol
; 12: 946850, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36818675
3.
Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer.
J Comp Eff Res
; 10(5): 353-364, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502247
4.
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.
J Comp Eff Res
; 9(16): 1117-1129, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33118841
5.
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.
J Med Econ
; 23(5): 448-455, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903807
6.
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.
Front Oncol
; 9: 849, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31616627
7.
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.
ESMO Open
; 3(4): e000353, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29765773
8.
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Mol Oncol
; 11(2): 208-219, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28106345